Elevated pulse pressure and cardiovascular risk associated in Spanish population attended in primary care: IBERICAN study.

Introduction: Elevated pulse pressure (ePP) is an independent marker of cardiovascular risk (CVR) in people older than 60, and a functional marker of subclinical target organ damage (sTOD) which can predict cardiovascular events in patients with hypertension (HTN), regardless of sTOD. Objective: To evaluate the prevalence of ePP in adult population seen in primary care and its association with other vascular risk factors, sTOD and with cardiovascular disease (CVD). Materials and methods: Observational multicentre study conducted in Spain (8,066 patients, 54.5% women) from the prospective cohort study IBERICAN recruited in Primary Care. Pulse pressure (PP) was defined as the difference between the systolic blood pressure (SBP) and the diastolic blood pressure (DBP) ≥60 mmHg. Adjusted (for age and sex) ePP prevalence were determined. Bivariate and multivariate analyses of the possible variables associated with ePP were carried out. Results: The mean of PP was 52.35 mmHg, and was significantly higher (p < 0.001) in patients with HTN (56.58 vs. 48.45 mmHg) The prevalence of ePP adjusted for age and sex was 23.54% (25.40% men vs. 21.75% women; p < 0.0001). The ePP prevalence rates increased linearly with age (R2 = 0.979) and were significantly more frequent in population aged ≥65 than in population aged <65 (45.47% vs. 20.98%; p < 0.001). HTN, left ventricular hypertrophy, low estimated glomerular filtration rate, alcohol consumption, abdominal obesity, and CVD were independently associated with ePP. 66.27% of patients with ePP had a high or very high CVR, as compared with 36.57% of patients without ePP (OR: 3.41 [95% CI 3.08-3.77]). Conclusions: The ePP was present in a quarter of our sample, and it was increased with the age. Also, the ePP was more frequent in men, patients with HTN, other TOD (as left ventricular hypertrophy or low estimated glomerular filtration rate) and CVD; because of this, the ePP was associated a higher cardiovascular risk. In our opinion, the ePP is an importer risk marker and its early identification lets to improve better diagnostic and therapeutic management.

Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage.

The role of uric acid levels in the cardiovascular continuum is not clear. Our objective is to analyze the prevalence of hyperuricemia (HU) and its association with cardiovascular risk factors (CVRF), subclinical target organ damage (sTOD), and cardiovascular diseases (CVD). We evaluated the prevalence of HU in 6.927 patients included in the baseline visit of the IBERICAN study. HU was defined as uric acid levels above 6 mg/dL in women, and 7 mg/dL in men. Using adjusted logistic regression models, the odds ratios were estimated according to CVRF, sTOD, and CVD. The prevalence of HU was 16.3%. The risk of HU was higher in patients with pathological glomerular filtration rate (aOR: 2.92), heart failure (HF) (aOR: 1.91), abdominal obesity (aOR: 1.80), hypertension (HTN) (aOR: 1.65), use of thiazides (aOR: 1.54), left ventricular hypertrophy (LVH) (aOR: 1.36), atrial fibrillation (AFIB) (aOR: 1.29), and albuminuria (aOR: 1.27). On the other hand, being female (aOR: 0.82) showed a reduced risk. The prevalence of HU was higher in men, in patients presenting CVRF such as HTN and abdominal obesity, and with co-existence of LVH, atrial fibrillation (AFIB), HF, and any form of kidney injury. These associations raise the possibility that HU forms part of the early stages of the cardiovascular continuum. This may influence its management in Primary Healthcare because the presence of HU could mean an increased CV risk in the patients.

Prevalencia de la enfermedad renal crónica y factores asociados en la población asistida en atención primaria de España: resultados del estudio IBERICAN / Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study

Objetivos: Conocer la prevalencia de enfermedad renal crónica (ERC) y determinar los factores asociados al deterioro de la función renal en población asistida en atención primaria.Pacientes y métodoEstudio transversal y multicéntrico realizado en los pacientes basales del estudio IBERICAN (identificación de la población española de riesgo cardiovascular y renal). Se consideró ERC a un filtrado glomerular estimado (FGe)<60ml/min/1,73m2 o albuminuria elevada (≥30mg/g). Según el FGe se clasificó la ERC en 6 estadios (1, 2, 3a, 3b, 4 y 5) y según la albuminuria en 3 (A1 o normal/ligeramente aumentada, A2 o moderadamente aumentada y A3 o gravemente aumentada). Se analizaron las características clínicas y la relación de la ERC con los principales factores de riesgo cardiovascular (FRCV) y otras variables de interés mediante regresión logística no condicional.ResultadosSe incluyeron 7.895 pacientes (edad media 57,9±14,8 años; 54,5% mujeres). El 14,4% (IC 95%: 13,6-15,1) presentaba ERC; en hombres un 16,1% (IC 95%: 14,9-17,3) y en mujeres un 12,9% (IC 95%: 11,9-14,0). Se observó un aumento continuo de la prevalencia con la edad (24,8%≥65años) y con la agregación de FRCV. Las variables que más se asociaron a la probabilidad de padecer ERC fueron hipertrofia ventricular izquierda (OR: 1,95; p<0,001), diabetes (OR: 1,58; p<0,001) e hipertensión (OR: 1,56; p<0,001).ConclusionesCatorce de cada 100 pacientes incluidos en el estudio IBERICAN presenta ERC. La prevalencia de ERC afecta a la cuarta parte de pacientes≥65 años y aumenta exponencialmente con la agregación de FRCV. (AU)

Objectives: To determine the prevalence of chronic kidney disease (CKD) and the factors associated with impaired renal function in the population attended in primary care (PC).Patients and methodCross-sectional and multicentre study carried out in the baseline patients of the IBERICAN study (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal). CKD was considered with an estimated glomerular filtration (eGF) <60ml/min/1.73 m2 or elevated albuminuria (≥ 30mg/g). According to the eGF, the CKD was classified in six stages (1, 2, 3a, 3b, 4 and 5) and according to albuminuria in three stages (A1 or normal / slightly increased, A2 or moderately increased and A3 or severely increased). The clinical characteristics and the relationship of CKD with the main cardiovascular risk factors (CVRF) and other variables of interest were analysed using unconditional logistic regression.Results7,895 patients were included (mean age 57.9±14.8 years; 54.5% women). 14.4% (95% CI: 13.6-15.1) had CKD; 16.1% (95% CI: 14.9-17.3) in men and 12.9% (95% CI: 11.9-14.0) in women. A continuous increase of the prevalence was observed with age (24.8% in≥65 years) and with CVFR aggregation. The variables that were most associated with the probability of suffering CKD were left ventricular hypertrophy (OR: 1.95; p <.001), diabetes (OR: 1.58; P<.001) and hypertension (OR: 1.56; P<.001).ConclusionsFourteen out of every 100 patients included in the IBERICAN study have CKD. The prevalence of CKD affects a quarter of patients ≥ 65 years and increases exponentially with the aggregation of FRCV. (AU)

Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study. / Prevalencia de la enfermedad renal crónica y factores asociados en la población asistida en atención primaria de España: resultados del estudio IBERICAN.

OBJECTIVES: To determine the prevalence of chronic kidney disease (CKD) and the factors associated with impaired renal function in the population attended in primary care (PC). PATIENTS AND METHOD: Cross-sectional and multicentre study carried out in the baseline patients of the IBERICAN study (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal). CKD was considered with an estimated glomerular filtration (eGF) <60ml/min/1.73 m2 or elevated albuminuria (≥ 30mg/g). According to the eGF, the CKD was classified in six stages (1, 2, 3a, 3b, 4 and 5) and according to albuminuria in three stages (A1 or normal / slightly increased, A2 or moderately increased and A3 or severely increased). The clinical characteristics and the relationship of CKD with the main cardiovascular risk factors (CVRF) and other variables of interest were analysed using unconditional logistic regression. RESULTS: 7,895 patients were included (mean age 57.9±14.8 years; 54.5% women). 14.4% (95% CI: 13.6-15.1) had CKD; 16.1% (95% CI: 14.9-17.3) in men and 12.9% (95% CI: 11.9-14.0) in women. A continuous increase of the prevalence was observed with age (24.8% in≥65 years) and with CVFR aggregation. The variables that were most associated with the probability of suffering CKD were left ventricular hypertrophy (OR: 1.95; p <.001), diabetes (OR: 1.58; P<.001) and hypertension (OR: 1.56; P<.001). CONCLUSIONS: Fourteen out of every 100 patients included in the IBERICAN study have CKD. The prevalence of CKD affects a quarter of patients ≥ 65 years and increases exponentially with the aggregation of FRCV.

Características basales y manejo clínico de los primeros 3.000 pacientes incluidos en el estudio IBERICAN (Identificación de la población española de riesgo cardiovascular y renal) / Baseline characteristics and clinical management of the first 3.000 patients enrolled in the IBERICAN study (Identification of the Spanish population at cardiovascular and renal risk)

Objetivos. Determinar la prevalencia y la incidencia de los factores de riesgo cardiovascular en España, así como de los eventos cardiovasculares, en población adulta española asistida en atención primaria. Metodología. IBERICAN es un estudio longitudinal, observacional y multicéntrico en el que se están incluyendo pacientes de 18 a 85años atendidos en las consultas de atención primaria en España. La cohorte obtenida se seguirá anualmente durante al menos 5años. La muestra final estimada es de 7.000 pacientes. Se presentan las características basales del segundo corte (n=3.042). Resultados. La edad media de los sujetos incluidos es de 57,9±14,6años, y el 55,5% son mujeres. El 54,9% viven en un hábitat urbano, y el 57,3% tienen estudios primarios. El 50,3% tienen dislipidemia, el 47,4% hipertensión arterial, el 29,7% sedentarismo, el 28,2% obesidad abdominal y el 19% diabetes mellitus. El grado de control de hipertensión arterial, dislipidemia y diabetes mellitus tipo2 fue del 58,5, del 25,8 y del 75,9%, respectivamente. El 28,2% cumplen criterios de síndrome metabólico. El 15,6% de los pacientes presentaban una enfermedad cardiovascular previa. El 7,8% tienen antecedentes de cardiopatía isquémica, el 8,4% de filtrado glomerular (CKD-EPI) <60ml/min, el 9,6% de microalbuminuria, el 5,5% de fibrilación auricular, el 4,6% de ictus y el 2,9% de insuficiencia cardiaca. Conclusiones. A pesar de que la población atendida en atención primaria es relativamente joven, la elevada prevalencia de factores de riesgo, su mal control y la existencia de patología cardiovascular previa condicionarán el impacto en el pronóstico de la cohorte (AU)

Objectives. To determine the prevalence and incidence of cardiovascular risk factors in Spain, as well as cardiovascular events, in Spanish adult population attended in primary care. Methodology. IBERICAN is a longitudinal, observational, multicenter study in which patients aged 18 to 85years attended in primary care health center in Spain are being included. The obtained cohort will be followed annually for at least 5years. The estimated final sample is 7,000 patients. The baseline characteristics of the second cut (n=3,042) are presented. Results. The mean age of the subjects included is 57.9±14.6 years, and 55.5% are women. 54.9% live in urban habitat, and 57.3% have primary education. 50.3% had dyslipidemia, 47.4% hypertension, 29.7% physical inactivity, 28.2% abdominal obesity and 19% diabetes mellitus. The degree of control of hypertension, dyslipidemia and type2 diabetes was 58.5%, 25.8% and 75.9%. 28.2% have criteria for metabolic syndrome. 15.6% of patients had previous cardiovascular disease. 7.8% have a history of coronary heart disease, a glomerular filtration rate <60ml/min (CKD-EPI) 8.4%, microalbuminuria 9.6%, atrial fibrillation 5.5%, stroke 4.6%, and heart failure 2.9%. Conclusions. Although the population treated in primary care is relatively young, the high prevalence of risk factors, their poor control and the existence of previous cardiovascular disease will determine the impact on the prognosis of the cohort (AU)

[Baseline characteristics and clinical management of the first 3,000 patients enrolled in the IBERICAN study (Identification of the Spanish population at cardiovascular and renal risk)]. / Características basales y manejo clínico de los primeros 3.000 pacientes incluidos en el estudio IBERICAN (Identificación de la población española de riesgo cardiovascular y renal).

OBJECTIVES: To determine the prevalence and incidence of cardiovascular risk factors in Spain, as well as cardiovascular events, in Spanish adult population attended in primary care. METHODOLOGY: IBERICAN is a longitudinal, observational, multicenter study in which patients aged 18 to 85years attended in primary care health center in Spain are being included. The obtained cohort will be followed annually for at least 5years. The estimated final sample is 7,000 patients. The baseline characteristics of the second cut (n=3,042) are presented. RESULTS: The mean age of the subjects included is 57.9±14.6 years, and 55.5% are women. 54.9% live in urban habitat, and 57.3% have primary education. 50.3% had dyslipidemia, 47.4% hypertension, 29.7% physical inactivity, 28.2% abdominal obesity and 19% diabetes mellitus. The degree of control of hypertension, dyslipidemia and type2 diabetes was 58.5%, 25.8% and 75.9%. 28.2% have criteria for metabolic syndrome. 15.6% of patients had previous cardiovascular disease. 7.8% have a history of coronary heart disease, a glomerular filtration rate <60ml/min (CKD-EPI) 8.4%, microalbuminuria 9.6%, atrial fibrillation 5.5%, stroke 4.6%, and heart failure 2.9%. CONCLUSIONS: Although the population treated in primary care is relatively young, the high prevalence of risk factors, their poor control and the existence of previous cardiovascular disease will determine the impact on the prognosis of the cohort.

Guías en el manejo de la hipertensión / Guidelines for the management of hypertension

En el último año, varias sociedades científicas han publicado sus guías para el manejo de la hipertensión arterial. En nuestro país, en los últimos años siempre han tenido mucha repercusión y seguimiento tanto la guía americana del National Heart, Lung and Blood Institute, cuyo último informe (JNC [Joint National Committee] 7) fue publicado en 2003, como las guías de las sociedades europeas de cardiología e hipertensión (European Society of Hypertension [ESH] y European Society of Cardiology [ESC]), cuya última guía databa del año 2007, aunque en 2009 se llevó a cabo una actualización. Este nuevo documento de las sociedades europeas ESH/ESC publicado en 2013 tiene un carácter fundamentalmente educacional, muy cercano al clínico, y aunque muchas de las recomendaciones mantienen el mismo criterio que guías previas, en esta ocasión el trabajo se ha hecho con un mayor rigor y se presenta con importantes aportaciones, como incorporar a cada una de las recomendaciones que se realiza los niveles de evidencia y el grado de recomendación, que es algo de lo que carecían las guías previas de estas sociedades. Es un documento sencillo, que de forma muy práctica se resume en 17 tablas, 5 figuras y 18 bloques de recomendaciones. Respecto al informe JNC 8, se presenta, sin embargo, como un documento con un solo objetivo, dar respuesta a 3 cuestiones que se consideran prioritarias, las cuales solamente son referidas al tratamiento farmacológico y de ellas se concluye con 9 recomendaciones (AU)

In the last year, several scientific societies have published guidelines for the management of arterial hypertension. In Spain, two clinical practice guidelines have had a strong impact and have been closely followed in the last few years: the first is the Guideline of the National Heart, Lung and Blood Institute, although their last report (JNC 7) was published in 2003; the second is the clinical practice guideline for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), whose latest version was published in 2007, although an update was published in 2009. A new ESC/ESH document, published in 2013, adopts a mainly educational stance, closely rooted in clinical practice. Many of the recommendations maintain the same criteria as previous guidelines. However, the new publication shows greater rigor and contains major contributions such as specification of the level of evidence and grade of recommendation for each recommendation, which was lacking in the previous guidelines of these societies. The document is both practical and easy to consult, consisting of 17 tables, 5 figures and 18 blocks of recommendations. The JNC 8 report, however, has a single objective: to respond to three questions that are considered a priority and which refer exclusively to drug therapy. Nine recommendations are made relating to these three questions (AU)

[Guidelines for the management of hypertension]. / Guías en el manejo de la hipertensión.

In the last year, several scientific societies have published guidelines for the management of arterial hypertension. In Spain, two clinical practice guidelines have had a strong impact and have been closely followed in the last few years: the first is the Guideline of the National Heart, Lung and Blood Institute, although their last report (JNC 7) was published in 2003; the second is the clinical practice guideline for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), whose latest version was published in 2007, although an update was published in 2009. A new ESC/ESH document, published in 2013, adopts a mainly educational stance, closely rooted in clinical practice. Many of the recommendations maintain the same criteria as previous guidelines. However, the new publication shows greater rigor and contains major contributions such as specification of the level of evidence and grade of recommendation for each recommendation, which was lacking in the previous guidelines of these societies. The document is both practical and easy to consult, consisting of 17 tables, 5 figures and 18 blocks of recommendations. The JNC 8 report, however, has a single objective: to respond to three questions that are considered a priority and which refer exclusively to drug therapy. Nine recommendations are made relating to these three questions.

Cardiovascular risk in women attending primary care centres: baseline data of the EVA study.

BACKGROUND: The purpose of this study was to determine the prevalence of hypertension, cardiovascular risk factors and target organ damage using baseline data from the EVA study. METHODS: EVA is a 5-year multicentre prospective study of women aged between 40 and 70 years attending primary care centres in a rural-urban area in the north of Spain. The recruitment period was between October 2009 and January 2010. The following variables were analysed: associated cardiovascular risk factors, target organ damage and cardiovascular or renal disease defined according to the 2007 European Society of Hypertension and the European Society of Cardiology Guidelines (2007 ESH/ESC 2007). Blood pressure <140/90 mmHg and <130/80 in diabetics were considered target blood pressure values. Cardiovascular risk was stratified according to the 2007 ESC-ESH guidelines. RESULTS: The study sample comprised of 903 women with a mean age of 59.6 ± 8 years. The prevalence of hypertension, Type 2 diabetes and dyslipidaemia was 45.6, 13.3 and 41.7%, respectively. Target organ damage affected 17.6% of women and manifested as microalbuminuria (1.8%), slight increase in plasma creatinine (1.6%) and left ventricular hypertrophy (2.9%). Overall, 9.3% had cardiovascular disease, 3.4% coronary heart disease, 1.8% heart failure, 1.8% peripheral artery disease and 1.4% renal disease; 2.2% of patients had experienced a stroke. The prevalence of cardiovascular risk factors in hypertensive women (HT) with respect to non-hypertensive women (NHT) was as follows: obesity 44.7 versus 18.9%, dyslipidaemia 48.8 versus 35.8% and Type 2 diabetes 21.8 versus 6.1%. The target organ damage was more prevalent in hypertensive women: 27.3 versus 9.4%. Cardiovascular disease was present in 14.8% of HT and 4.7% of NHT. High or very high cardiovascular risk affected 65.3% of HT and 26.9% of NHT. CONCLUSIONS: Four in 10 women attending primary care centres had a high or very high cardiovascular risk. Percentages of classic cardiovascular risk factors were higher in HT than in NHT and increased significantly with age. The most commonly used drugs were renin-angiotensin system blockers and diuretics.

Medida de la presión arterial en consulta y automatizada (BPTru®) para evaluar el efecto de bata blanca / Measurement of blood pressure in consultation and automated mesurement (BPTru ®) to evaluate the white coat effect

Fundamento y objetivo: El efecto de bata blanca (EBB) es uno de los principales sesgos que pueden modificar la medida de la presión arterial (PA) en consulta, por lo que se debe considerar para evitar errores diagnóstico-terapéuticos en los pacientes hipertensos. La utilización de aparatos automatizados en consulta podría disminuir dicho efecto. Método: Se diseñaron 2 estudios con el objetivo de evaluar las diferencias entre la medida rutinaria en consulta y la obtenida por el aparato automatizado de medida de PA en consulta, BPTru®, así como su influencia en el EBB. El primero de los estudios, TRUE-ESP, incluyó pacientes normotensos e hipertensos atendidos en consultas especializadas de Cardiología, Nefrología, Medicina Interna, Endocrinología y Medicina Familiar. El segundo, TRUE-HTA, incluyó pacientes hipertensos atendidos en una Unidad de HTA, protocolizada, con personal entrenado. Resultados: El estudio TRUE-ESP incluyó 300 pacientes, 76% hipertensos. Se observó una diferencia significativa entre la medida clínica y la medida BPTru® (media [DE] de PA sistólica/PA diastólica [PAS/PAD] de 9,8 [6,11]/3,4 [7,9] mmHg, p<0,001). El porcentaje de pacientes que cumplió criterios de EBB fue del 27,7%. El estudio TRUE-HTA incluyó 101 pacientes hipertensos. Se observó una diferencia significativa entre la medida clínica y la medida mediante BPTru® (media [DE] de PAS/PAD de 5,7 [3,9]/2,1 [3,5] mmHg, p<0,001) y la medida del período de actividad de la monitorización ambulatoria de la PA (MAPA) (media [DE] de PAS/PAD de 8,5 [6,7]/3,5 [2,5] mmHg, p<0,001). El porcentaje de pacientes que cumplió criterios de EBB fue del 32,1%. Conclusiones: El empleo de aparatos automatizados de medida de PA en consulta, como el BPTru®, puede colaborar a disminuir el EBB y mejorar la precisión de la medida de la PA en consulta (AU)

Background and objective: White coat effect (WCE) is one of the main bias that can affect office blood pressure (BP) measurement. Therefore, it is a factor must be considered in hypertensives to avoid mistakes in diagnosis and/or treatment. Employment of automated office BP (AOBP) devices could diminish that effect. Methods: Two studies were designed with the objective of evaluating differences between routinely office and AOBP measurements. WCE was also assessed. First, the TRUE-ESP study included normotensive and hypertensive patients attending specialized consultations at Cardiology, Nephrology, Internal Medicine, Endocrinology and Family Practice. Second, the TRUE-HTA study included hypertensives attending a protocoled Hypertension Unit, with a trained staff. Results: TRUE-ESP study included 300 patients, 76% being hypertensives. A significant difference between office BP and AOBP measurement (SBP/DBP 9.8±11.6/3.4±7.9mmHg, P<.001) was observed. Percentage of patients gathering WCE criteria was 27.7%. TRUE-HTA study included 101 hypertensive patients. A significant difference between office BP and AOBP measurement (SBP/DBP 5.7±9.3/2.1±5.3mmHg, P<.001) and activity period-ABPM (SBP/DBP 8.5±6.7/3.5±2.5mmHg, P<.001) was observed. Percentage of WCE patients was 32.1%. Conclusions: Use of AOBP devices can contribute to decrease WCE and to improve accuracy of office BP measurement (AU)

[Measurement of blood pressure in consultation and automated mesurement (BPTru(®)) to evaluate the white coat effect]. / Medida de la presión arterial en consulta y automatizada (BPTru®) para evaluar el efecto de bata blanca.

BACKGROUND AND OBJECTIVE: White coat effect (WCE) is one of the main bias that can affect office blood pressure (BP) measurement. Therefore, it is a factor must be considered in hypertensives to avoid mistakes in diagnosis and/or treatment. Employment of automated office BP (AOBP) devices could diminish that effect. METHODS: Two studies were designed with the objective of evaluating differences between routinely office and AOBP measurements. WCE was also assessed. First, the TRUE-ESP study included normotensive and hypertensive patients attending specialized consultations at Cardiology, Nephrology, Internal Medicine, Endocrinology and Family Practice. Second, the TRUE-HTA study included hypertensives attending a protocoled Hypertension Unit, with a trained staff. RESULTS: TRUE-ESP study included 300 patients, 76% being hypertensives. A significant difference between office BP and AOBP measurement (SBP/DBP 9.8±11.6/3.4±7.9 mmHg, P<.001) was observed. Percentage of patients gathering WCE criteria was 27.7%. TRUE-HTA study included 101 hypertensive patients. A significant difference between office BP and AOBP measurement (SBP/DBP 5.7±9.3/2.1±5.3 mmHg, P<.001) and activity period-ABPM (SBP/DBP 8.5±6.7/3.5±2.5 mmHg, P<.001) was observed. Percentage of WCE patients was 32.1%. CONCLUSIONS: Use of AOBP devices can contribute to decrease WCE and to improve accuracy of office BP measurement.

Evaluación y control de los hipertensos diabéticos atendidos en centros de Atenci¨®n Primaria de España. Estudio BRAND II / Evaluation and control of hypertensive diabetics seen in Primary Care centres in Spain. BRAND II study

ObjetivoEstudiar el grado de control y el tratamiento empleado en los hipertensos diab¨¦ticos atendidos en los centros de Atenci¨®n Primaria en España.DiseñoEstudio descriptivo realizado a pacientes hipertensos y diab¨¦ticos que acuden a consulta m¨¦dica de Atenci¨®n Primaria por cualquier motivo.EmplazamientoCentros de Atenci¨®n Primaria de todo el territorio nacional.ParticipantesSe incluyeron 6.777 pacientes.Mediciones principalesSe les determin¨® la presi¨®n arterial, peso, talla, per¨ªmetro de cintura, anal¨ªtica completa y tratamiento.ResultadosLa edad media de la muestra fue de 64,40¡À11,50 años. La glucosa media fue de 141,8¡À39mg/dl, la hemoglobina glicosilada fue < 7% en el 45,9% de la muestra y la presi¨®n arterial estaba controlada (PA<130/80 mmHg) en el 9,8% de los pacientes estudiados. El LDL colesterol era inferior a 100mg/dl en el 25,3% de los pacientes. Los f¨¢rmacos m¨¢s utilizados para el control de la diabetes fueron las sulfonilureas en 2.259 pacientes (33,1%) y las biguanidas en 3.768 pacientes (55,6%). Estaban en tratamiento con insulina 556 pacientes, lo que representa el 8,2%. Respecto a la hipertensi¨®n arterial los f¨¢rmacos m¨¢s utilizados fueron los diur¨¦ticos en 3.395 pacientes (50,1%) y los inhibidores de la enzima convertidora de angiotensina en 4.053 pacientes (59,8%)(AU)

ObjectiveWe aimed to verify the level of blood pressure and glucose control and treatment in hypertensive diabetics seen in Primary Care Centres in Spain.DesignDescriptive study conducted on hypertensive diabetic patients who attended primary care centres for any reason.LocationPrimary Care centres throughout Spain.ParticipantsThe study included 6,777 patients.MeasurementsBlood pressure, weight, height, waist circumference, blood analysis and treatment were recordedResultsThe mean age of the sample was 64.40 (11.50) years. Mean blood glucose was 141.8 (39) mg/dl, glycosylated haemoglobin was ¡Ü7% in 45.9% of the sample, and blood pressure was under control (BP¡Ü130/80 mmHg) in 9.8% of the patients studied. LDL Cholesterol was ¡Ü100mg/dl in 25.3% of the sample. The drugs most used to control diabetes were; sulphonylureas 2259 patients (33.3%) and biguanides 3768 patients (55.6%). A total of 556 patients were on treatment with insulin, which represented 8.2% of the population studied. The drugs most used for hypertension were; diuretics in 3395 patients (50.1%) and angiotensin-converting enzyme inhibitors in 4053 patients (59.8%).ConclusionsA large proportion of hypertensive diabetics are insufficiently controlled(AU)

[Evaluation and control of hypertensive diabetics seen in Primary Care centres in Spain. BRAND II study]. / Evaluación y control de los hipertensos diabéticos atendidos en centros de Atención Primaria de España. Estudio BRAND II.

OBJECTIVE: We aimed to verify the level of blood pressure and glucose control and treatment in hypertensive diabetics seen in Primary Care Centres in Spain. DESIGN: Descriptive study conducted on hypertensive diabetic patients who attended primary care centres for any reason. LOCATION: Primary Care centres throughout Spain. PARTICIPANTS: The study included 6,777 patients. MEASUREMENTS: Blood pressure, weight, height, waist circumference, blood analysis and treatment were recorded RESULTS: The mean age of the sample was 64.40 (11.50) years. Mean blood glucose was 141.8 (39) mg/dl, glycosylated haemoglobin was ≤7% in 45.9% of the sample, and blood pressure was under control (BP≤130/80 mmHg) in 9.8% of the patients studied. LDL Cholesterol was ≤100mg/dl in 25.3% of the sample. The drugs most used to control diabetes were; sulphonylureas 2259 patients (33.3%) and biguanides 3768 patients (55.6%). A total of 556 patients were on treatment with insulin, which represented 8.2% of the population studied. The drugs most used for hypertension were; diuretics in 3395 patients (50.1%) and angiotensin-converting enzyme inhibitors in 4053 patients (59.8%). CONCLUSIONS: A large proportion of hypertensive diabetics are insufficiently controlled.

Utilización de mediciones antropométricas para predecir resistencia a la insulina / Use of anthropometric measures to predict insulin resistance

Objetivo: La obesidad está estrechamente relacionada con la resistencia a la insulina (RI), pero se valora de forma dispar en las diversas definiciones de síndrome metabólico. El objetivo del estudio fue comprobar la utilidad de distintas mediciones antropométricas para predecir RI y valorar los mejores puntos de corte. Sujetos y método: Estudio transversal sobre población de 40 a 70 años (2.143 habitantes); se obtuvo una muestra aleatoria simple de 305 pacientes no diabéticos. Se recogieron variables sociodemográficas, exploración y analítica habituales más insulinemia. Se consideró RI un índice de HOMA (homeostasis model assessment) $ 2,9. Se practicó una regresión logística por pasos hacia delante para obtener las mejores variables para predecir RI; después se construyó una ecuación logística y se comparó el área bajo la curva ROC (receiver operating characteristic) de ésta y de las distintas variables antropométricas en su capacidad de predicción, y los mejores puntos de corte según el índice de Youden. Resultados: Han entrado en el modelo el índice de masa corporal (IMC) y la razón cintura/cadera 3 100. No han entrado la edad, el sexo, la cintura, la cadera y la superficie corporal. La ecuación logística hallada: p(RI) = 1/1 + exp {­[­14,295] ­ [0,234 3 IMC] ­ [0,07 3 (cintura/cadera 3 100)]} mostró un buen ajuste, y la probabilidad calculada por ella presenta la mayor área en general y para cada sexo, seguida en mujeres por el IMC y en varones por la cintura, pero sin diferencias significativas. Conclusiones: No se ha encontrado diferencias significativas ente IMC, cintura, cadera y un modelo logístico para predecir la RI (AU)

Objective: Obesity is closely related to insulin-resistance (IR) but it is evaluated differently in the diverse definitions of the metabolic syndrome. The objective of this study was to verify the utility of different anthropometric measures to predict IR and to evaluate the best cut-off points. Subjects and method: We performed a cross-sectional study of the general population aged 40 to 70 years old (n = 2,143); a simple random sample of 305 non-diabetic persons was obtained. Sociodemographic data, physical examination and routine biochemical analysis with insulinemia were obtained. IR was defined by a HOMA index (Homeostasis Model Assessment) $ 2.9. To obtain the best variables to predict IR, a forward stepwise logistic regression was performed. Subsequently, a logistic equation was constructed and its predictive capacity was compared with the different anthropometric variables by the area under the ROC (receiver-operating characteristic) curve (AUC). The best cut-off points were established according to the Youden index. Results: Body mass index (BMI) and the waist/hip ratio 3 100 were entered into the model, but age, sex, waist, hip and body surface were not. The logistic equation found: p(RI) = 1/1 + exp{­[­14.295] ­ [0.234 3 IMC] ­ [0.07 3 (waist/hip 3 100)]} showed good adjustment, and the probability calculated on the basis of this equation showed the greatest AUC overall and in both sexes, followed in women by BMI and by waist measurement in men, but without significant differences. Conclusions: No significant differences were found between the BMI, waist or hip measurements and the logistic model to predict IR (AU)

Use of anthropometric measures to predict insulin resistance.

OBJECTIVE: Obesity is closely related to insulin-resistance (IR) but it is evaluated differently in the diverse definitions of the metabolic syndrome. The objective of this study was to verify the utility of different anthropometric measures to predict IR and to evaluate the best cut-off points. SUBJECTS AND METHOD: We performed a cross-sectional study of the general population aged 40 to 70 years old (n=2,143); a simple random sample of 305 non-diabetic persons was obtained. Sociodemographic data, physical examination and routine biochemical analysis with insulinemia were obtained. IR was defined by a HOMA index (Homeostasis Model Assessment) ≥2.9. To obtain the best variables to predict IR, a forward stepwise logistic regression was performed. Subsequently, a logistic equation was constructed and its predictive capacity was compared with the different anthropometric variables by the area under the ROC (receiver-operating characteristic) curve (AUC). The best cut-off points were established according to the Youden index. RESULTS: Body mass index (BMI) and the waist/hip ratio ×100 were entered into the model, but age, sex, waist, hip and body surface were not. The logistic equation found: p(RI)=1/1+exp{-[-14.295]-[0.234×IMC]-[0.07×(waist/hip×100)]} showed good adjustment, and the probability calculated on the basis of this equation showed the greatest AUC overall and in both sexes, followed in women by BMI and by waist measurement in men, but without significant differences. CONCLUSIONS: No significant differences were found between the BMI, waist or hip measurements and the logistic model to predict IR.

Comparación de los modelos SCORE y Framinghan en el cálculo de alto riesgo cardiovascular para una muestra de varones de 45 y 65 años de Asturias / Comparison of the SCORE and Framingham Models in Calculating High Cardiovascular Risk for a Sample of Males within the 45-65 Age Range in Asturias, Spain

Fundamento: Recientemente el Comité Español Interdisciplinariopara la Prevención Cardiovascular (CEIP) elaboró un consensopara adaptar las recomendaciones de la Guía Europea de Prevencióncardiovascular a la población española, utilizando el SCOREcomo método de cálculo de riesgo. El objetivo de este trabajo esconocer las diferencias que supone pasar del criterio de Framinghamal de SCORE en la clasificación de los varones en el grupo de altoriesgo.Métodos: Estudio descriptivo transversal realizado en atenciónprimaria. El número de participantes fue de 379 varones de entre 45y 65 años, correspondientes a 4 cupos de medicina general de 3 centrosde salud del Principado de Asturias. Medidas principales: cálculodel riesgo cardiovascular y prevalencia de alto riesgo según Framinghamclásico y según SCORE. Estimación de curva de prevalenciade alto riesgo por regresión logística.Resultados: La prevalencia de alto riesgo según la ecuación deFramingham fue de 24% (IC95%=19,9-28,7) y según SCORE de17,9% (IC95%=14,3-22,3) siendo la diferencia estadísticamente significativa(p=0,02). El modelo SCORE presenta prevalencias menoresen sujetos menores de 60 años y mayores por encima de los 60; envarones fumadores SCORE presenta prevalencias menores en personasmenores de 58 años; los varones de alto riesgo con Framinghamy bajo riesgo con SCORE son más jóvenes, fumadores y con cifrasmedias más bajas de presión arterial y cifras moderadas de colesterol.Conclusiones: Al aplicar el modelo SCORE clasificamos menosvarones como de alto riesgo, sobre todo en menores de 58 años,fumadores y con cifras moderadas de colesterol, que con la escala deFramingham

Background: The Spanish Interdisciplinary Committee forCardiovascular Prevention has recently drafted a consensus foradapting the European Cardiovascular Prevention Guide to theSpanish population, using SCORE as the risk-calculation method.This study is aimed as ascertaining the differences involved inchanging over from the Framingham to the SCORE criterion in theclassification of males within the high-risk group.Methods: Descriptive cross-sectional study conducted in primarycare. A total of 379 males within the 45-65 age range, correspondingto four (4) groups from general practitioners from threehealthcare centers in the Principality of Asturias. Main measurements:calculation of the cardiovascular risk and high-risk prevalenceby the conventional Framingham method and according to SCORE.High-risk prevalence curve estimated by logic regression.Results: The high-risk prevalence according to the Framinghamequation was 24% (CI95%=19.9-28.7) and was 17.9%(CI95%=14.3-22.3) for SCORE, the difference being statistically significant(p=0.02). The SCORE model shows lower prevalencesamong subjects under age 60 and higher for those over age 60.Among male smokers, SCORE shows lower prevalences among individualsunder 58 years of age, the high-risk males with Framinghamand low-risk with SCORE being younger, smokers and having loweraverage blood pressure figures and moderate cholesterol figures.Conclusions: On applying the SCORE model, we classify fewermales as high-risk, especially among those under 58 years of agewho are smokers having moderate cholesterol figures than when theFramingham scale is used

[Differences in the prevalence of metabolic syndrome according to the ATP-III and WHO definitions]. / Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP-III y la OMS.

BACKGROUND AND OBJECTIVE: The objective of the study is to know the prevalence of the metabolic syndrome (MS), as well as to know the differences in its prevalence according to the Adult Treatment Panel of the National Cholesterol Education Program (ATP-III) and World Health Organization (WHO) criteria. PATIENTS AND METHOD: Cross-sectional descriptive study performed in primary care in population of both sexes aged between 40 and 74 years. Variables studied were risk factors as well as each one of the components of MS, according to both definitions. RESULTS: We studied 358 patients, 161 (45%) men and 197 women. The prevalence of MS using the WHO criteria was 17.9% and according with the ATP-III criteria it was 23.5%. The prevalence increased with age and the body mass index. Both definitions agreed in the classification of MS in 80% of cases (kappa = 0.38). If we considered the definition of MS according to the WHO taken as the "gold standard", the ATP-III definition displays a sensitivity of 59.4%, specificity of 84.4% and negative predictive value of 90.5%. The agreement is greater in women and older than 60 years. CONCLUSIONS: The prevalence of MS is smaller with the WHO criteria. The agreement between both methods is scarce and the clinical application of the ATP-III criteria in primary care needs its homologation with clinic-epidemiological studies.

Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP-III y la OMS / Differences in the prevalence of metabolic syndrome according to the ATP-III and WHO definitions

FUNDAMENTO Y OBJETIVO: El objetivo del estudio fue conocer y comparar las diferencias en la prevalencia del síndrome metabólico (SM) estimada según las definiciones del Adult Treatment Panel III the National Cholesterol Education Program (ATP-III) y de la Organización Mundial dela Salud (OMS).PACIENTES Y MÉTODO: Estudio descriptivo transversal en atención primaria, en población de 40 a74 años. Se estudiaron los factores de riesgo así como cada uno de los componentes del SM, según ambas definiciones. RESULTADOS: Estudiamos a 358 pacientes, 161 (45%) varones y 197 mujeres. La prevalencia del SM según criterios de la OMS fue del 17,9% y según los del ATP-III, del 23,5%. Esta prevalencia aumenta con la edad y con el índice de masa corporal. Ambas definiciones coinciden en la clasificación en el 80% de los casos (índice de kappa = 0,38). Considerando de referencia la definición de la OMS, el ATP-III presenta una sensibilidad del 59,4%, una especificidad del 84,4% y un valor predictivo negativo del 90,5%, y la concordancia mayor en mujeres y en pacientes mayores de 60 años. CONCLUSIONES: La prevalencia del SM es menor con los criterios de la OMS. La concordancia entre los criterios de la OMS y los del ATP III es escasa. La aplicación clínica de los criterios del ATP-III en atención primaria precisa su homologación con estudios clinic epidemiológicos

BACKGROUND AND OBJECTIVE: The objective of the study is to know the prevalence of the metabolic syndrome (MS), as well as to know the differences in its prevalence according to the Adult Treatment Panel of the National Cholesterol Education Program (ATP-III) and World Health Organization(WHO) criteria. PATIENTS AND METHOD: Cross-sectional descriptive study performed in primary care in population f both sexes aged between 40 and 74 years. Variables studied were risk factors as well as each one of the components of MS, according to both definitions. RESULTS: We studied 358 patients, 161 (45%) men and 197 women. The prevalence of MSusing the WHO criteria was 17.9% and according with the ATP-III criteria it was 23,5%. The prevalence increased with age and the body mass index. Both definitions agreed in the classification of MS in 80% of cases (kappa = 0.38). If we considered the definition of MS according to the WHO taken as the «gold standard», the ATP-III definition displays a sensitivity of59.4%, specificity of 84.4% and negative predictive value of 90.5%. The agreement is greater in women and older than 60 years. CONCLUSIONS: The prevalence of MS is smaller with the WHO criteria. The agreement between both methods is scarce and the clinical application of the ATP-III criteria in primary care needs its homologation with clinic-epidemiologal studies